期刊文献+

盐酸美利曲辛多晶型的制备与表征

Preparation and Characterization of Melitracen Hydrochloride Polymorphs
原文传递
导出
摘要 制备了盐酸美利曲辛的7种晶型[Ⅰ、Ⅱ、A、B、C、D(一水合物)、E晶型],利用粉末X射线衍射法、差示扫描量热法、热重法、红外光谱法分别对7种晶型物质状态进行了表征分析;其中,A、B、C、D(一水合物)及E晶型为首次报道。通过影响因素试验探讨了7种晶型的稳定性与晶型转变规律,结果表明,Ⅰ、Ⅱ、A三种晶型为稳定晶型,B、C、E晶型在高湿[相对湿度(90±5)%]条件下转变为D晶型,B晶型在高温[(60±2)℃]条件下转变为E晶型,D晶型在高温[(60±2)℃]条件下失去结晶水转变为A晶型。本研究还对盐酸美利曲辛在无水乙醇中的不同结晶工艺条件下析出产物晶型的情况进行研究,结果表明搅拌速率、析晶温度对产物晶型有着重大的影响。 In this paper, the melitracen hydrochloride polymorphs [form Ⅰ, Ⅱ, A, B, C, D (monohydrate), E] were prepared. The polymorphs were characterized by powder X-ray diffraction, differential scanning calorimetry, thermal gravimetric analysis and attenuated total reflectance-Fourier transform infrared spectroscopy. Among them, form A, B, C, D (monohydrate) and E were reported for the first time. Furthermore, the stability and the transformation were explored. Form Ⅰ, Ⅱand A were the stable forms. Form B, C and E were metastable forms which could transform to form D under high humidity condition [RH (90±5) % ]. Form B could transform to form E, and form D could transform to anhydrous form A at (60±2) ℃. In this article, the crystallization processes of melitracen hydrochloride in anhydrous ethanol were studied, and it was found that the stirring rate and crystallization temperature had significant influences on the form formation.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2017年第10期1508-1513,共6页 Chinese Journal of Pharmaceuticals
关键词 盐酸美利曲辛 多晶型 晶型表征 稳定性 结晶 melitracen hydrochloride polymorph characterization stability crystallization
  • 相关文献

参考文献5

二级参考文献20

  • 1冒莉,郑启泰,吕扬.固体药物多晶型的研究进展[J].天然产物研究与开发,2005,17(3):371-375. 被引量:48
  • 2王祖新.抗抑郁药[A].见:沈渔主编.精神病学:第4版[C].北京:人民卫生出版社,2001.681~703.
  • 3王祖新.精神病的治疗和精神药理学发展概况[A].见:苏怀德主编.药物研究史选讲[C].北京:北京医科大学、协和医科大学联合出版社,1992.29~34.
  • 4[1]Cross A.J,Owen F.Characteristics of JH-Cis-fupenthixol binding to calf brain membranes[J].Eur J PharmaCol,1980,65:4.
  • 5[2]Cermak I,Ringel R.CliniCal experiences with the new psychoactivator Deanxit (Melitracen and Flupenthixol)[J].Schweiz Rundsch Med Prax,1971,60:757-762.
  • 6[3]Brasseur R.Proceedings of mixed arolietydepressicve disorders with Psychosomatic Symptomatology Symposium held in copenhagen[J].Denmark,1985.21-28.
  • 7HILF1KER R. Polymorphism: in the Pharmaceutical Industry [ M ]. Wiley, 2006.
  • 8BRITTAIN HG, BUCKTON G. Polymorphism in pharmaceutical solids [ J ]. Eur J Pharm Biopharm, 2000, 49 (2) : 195.
  • 9吕扬,郑启泰.中草药现代研究(仪器分析卷)[M].北京:北京医科大学/协和医科大学联合出版社,1998:366-388.
  • 10YU L. Amorphous pharmaceutical solids: preparation, character- ization and stabilization[J]. Adv Drug Deliv Rev, 2001, 48( 1 ) : 27 - 42.

共引文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部